Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) Research & Development (2023 - 2025)

Upstream Bio (UPB) has 3 years of Research & Development data on record, last reported at $33.0 million in Q3 2025.

  • For Q3 2025, Research & Development rose 113.67% year-over-year to $33.0 million; the TTM value through Sep 2025 reached $118.4 million, up 141.75%, while the annual FY2024 figure was $63.0 million, 98.01% up from the prior year.
  • Research & Development reached $33.0 million in Q3 2025 per UPB's latest filing, down from $37.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $37.9 million in Q2 2025 and bottomed at $7.8 million in Q3 2023.
  • Average Research & Development over 3 years is $20.9 million, with a median of $18.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 98.16% in 2024, then skyrocketed 169.14% in 2025.
  • A 3-year view of Research & Development shows it stood at $7.8 million in 2023, then surged by 179.57% to $21.8 million in 2024, then surged by 51.45% to $33.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $33.0 million in Q3 2025, $37.9 million in Q2 2025, and $25.8 million in Q1 2025.